Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology Company

Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed
Biotechnology Company

Company Announcement

  *Research collaboration with an undisclosed large Biotechnology company for
    DuoBody^(R) and HexaBody^TM technology platforms
  *Genmab's first HexaBody collaboration

COPENHAGEN, Denmark, June 4, 2014 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN), together with its subsidiary, Genmab B.V., announced today a
research collaboration with an undisclosed Biotechnology company which would
use and evaluate Genmab's proprietary antibody technologies, the DuoBody and
HexaBody platforms. 

"We are enthusiastic to enter our first research collaboration for the
HexaBody technology which was unveiled just over a year ago. This exciting
technology has the potential to enhance antibody efficacy in a fundamentally
new way. We are also very pleased to enter another DuoBody platform
collaboration and we look forward to exploring the therapeutic potential of
products incorporating the HexaBody and DuoBody technologies with this major
Biotechnology company," said Jan van de Winkel, Ph.D., Chief Executive Officer
of Genmab.

The financial terms of the agreement have not been disclosed. This agreement
will not have a material impact on Genmab's financial results and cash
position.

About the DuoBody Platform

The DuoBody platform is an innovative platform for the discovery and
development of bispecific antibodies that may improve antibody therapy of
cancer, autoimmune, infectious and central nervous system disease. Bispecific
antibodies bind to two different epitopes either on the same, or on different
targets (also known as dual-targeting) which may improve the antibodies'
specificity and efficacy in inactivating the disease targets. DuoBody
molecules are unique in combining the benefits of bispecificity with the
strengths of conventional antibodies which allows DuoBody molecules to be
administered and dosed as other antibody therapeutics. Genmab's DuoBody
platform generates bispecific antibodies via a fast and broadly applicable
process which is easily performed at standard bench, as well as commercial,
manufacturing scale.

About HexaBody technology

HexaBody technology, a broadly applicable antibody platform from Genmab,
allows for the creation of potent therapeutics by inducing antibody hexamer
formation (clusters of six antibodies). The HexaBody platform builds on
natural antibody biology and enhances complement-mediated killing
(complement-dependent cytotoxicity (CDC)), allowing antibodies with limited or
absent CDC to be transformed into potent cytotoxic antibodies. The HexaBody
technology creates opportunities to explore new product candidates, to
repurpose drug candidates unsuccessful in previous clinical trials due to
insufficient potency and may provide a useful strategy in product life cycle
extension. The HexaBody technology can be directed to any antigen or target,
including those implicated in cancer and infectious diseases. The HexaBody
technology can be combined with Genmab's DuoBodyplatform as well as other
antibody technologies.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company currently has one
marketed antibody, Arzerra^(R) (ofatumumab) for the treatment of certain
chronic lymphocytic leukemia indications, a clinical pipeline with both late
and early stage programs, and an innovative preclinical pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody platform for generation of bispecific antibodies,
and the HexaBody platform which creates effector function enhanced
antibodies. Genmab's deep antibody expertise is expected to provide a stream
of future product candidates. Partnering of selected innovative product
candidates and technologies is a key focus of Genmab's strategy and the
company has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com

Contact:

Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^(R); the
Y-shaped Genmab logo^(R); Genmab in combination with the Y-shaped Genmab
logo^TM; the DuoBody logo^TM; HuMax^(R); HuMax-CD20^(R); DuoBody^(R),
HexaBody^TM and UniBody^(R). Arzerra^(R) is a registered trademark of
GlaxoSmithKline.

Company Announcement no. 30
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
 
Press spacebar to pause and continue. Press esc to stop.